Your browser doesn't support javascript.
loading
Automated ELISA for potency measurements of therapeutic antibodies and antibody fragments.
Rey, Guillaume; Schuetz, Fabienne; Schroeder, Daniela; Kaluschke, Christian; Wendeler, Markus W; Hofmann, Irmgard; Dumbliauskas, Eva; Obrdlik, Petr.
Affiliation
  • Rey G; Novartis Pharma AG, Technical Research and Development Biologics, Analytical Development Bioanalytics, Basel, Switzerland.
  • Schuetz F; Novartis Pharma AG, Technical Research and Development Biologics, Analytical Development Bioanalytics, Basel, Switzerland.
  • Schroeder D; Current address: EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, Germany.
  • Kaluschke C; Novartis Pharma AG, Technical Research and Development Biologics, Analytical Development Bioanalytics, Basel, Switzerland.
  • Wendeler MW; Current address: Analytical Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach a. d. R., Germany.
  • Hofmann I; Current address: TA Oncology, Boehringer Ingelheim International GmbH, Ingelheim, Germany.
  • Dumbliauskas E; Novartis Pharma AG, Technical Research and Development Biologics, Analytical Development Bioanalytics, Basel, Switzerland.
  • Obrdlik P; Novartis Pharma AG, Technical Research and Development Biologics, Analytical Development Bioanalytics, Basel, Switzerland. Electronic address: petr.obrdlik@novartis.com.
J Pharm Biomed Anal ; 245: 116141, 2024 Aug 01.
Article in En | MEDLINE | ID: mdl-38678856
ABSTRACT
Potency assays are essential for the development and quality control of biopharmaceutical drugs, but they are often a time limiting factor due to manual handling steps and consequently low analytical throughput. On the other hand, automation of potency assays can be challenging due to their complexity and the use of biological materials. ELISA (enzyme-linked immunosorbent assay) is widely used for potency determination and is a good candidate for automation as all ELISA types depend on the same basic

steps:

coating, blocking, sample incubation, detection, and signal measurement. Nevertheless, ELISA for relative potency measurements still require drug-specific development and assay validation thereby complicating automation efforts. To simplify potency testing by ELISA, we first developed a manual protocol generally applicable to different drugs and then adapted this protocol for automated measurements. We identified unexpected critical parameters which had to be adapted to transfer the manual ELISA to an automated liquid handling system and we demonstrated that gravimetric sample dilution is unnecessary with the automated protocol. Both manual and automated protocols were validated and compared using multiple biotherapeutics. The automated protocol showed similar or higher precision and accuracy when compared to the manual method.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Enzyme-Linked Immunosorbent Assay Limits: Humans Language: En Journal: J Pharm Biomed Anal Year: 2024 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Enzyme-Linked Immunosorbent Assay Limits: Humans Language: En Journal: J Pharm Biomed Anal Year: 2024 Document type: Article Affiliation country: